Evidence map›Paper›PMID 40784905›Full record

ArticleScientific reports2025

SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.

Nwachukwu William Enyereibe, Elsie Ilori, Laura Steinhardt, Kristen Stafford, Chioma Dan-Nwafor, Chinwe Lucia Ochu, Dalhatu Ibrahim, Matthias Alagi, Baffa Sule Ibrahim, Iwara Emem Iwara and 30 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Nwachukwu William EnyereibeNigeria Centre for Disease Control and Prevention, Abuja, Nigeria. drj_nwachukwuwe@yahoo.com.
Elsie IloriNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Laura SteinhardtDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Kristen StaffordUniversity of Maryland School of Medicine United States of America USA, Baltimore, USA.
Chioma Dan-NwaforNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Chinwe Lucia OchuNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Dalhatu IbrahimDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Matthias AlagiDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Baffa Sule IbrahimCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Iwara Emem IwaraCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Nwando MbaNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Zainab IbrahimNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Rabiatu Aliyu AhmedNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Iliya BotsonNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Stanley Uche OgbonnaNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Ehimario IgumborCenter for Infectious Disease Research, Nigerian Institute of Medical Research, Lagos, Nigeria.
Jafiya AbubakarNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Nasir AhmedNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Gloria Ogochukwu NwiyiNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Chima Emmanuel IhemejeNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Catherine OkoiNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Doris JohnFederal Capital Territory (FCT) Ministry of Health, Abuja FCT, Nigeria.
Matthew AshikeniFederal Capital Territory (FCT) Ministry of Health, Abuja FCT, Nigeria.
Basheer Lawan MuhammadKano State Ministry of Health, Kano, Nigeria.
Nnaemeka C IriemenamDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Olumide OkunoyeDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Stacie M GrebyDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Orji BasseyDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
McPaul OkoyeDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Natalia BlancoUniversity of Maryland School of Medicine United States of America USA, Baltimore, USA.
Andrew MitchellUniversity of Maryland School of Medicine United States of America USA, Baltimore, USA.
Oladipupo IpadeolaDivision of Global Health Protection, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Gladys S AntonzaCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Augustine MpamugoCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Favour MakavaCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Manhattan CharuratUniversity of Maryland School of Medicine United States of America USA, Baltimore, USA.
Sylvia AdebajoCenter for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Federal Capital Territory, Baltimore, Nigeria.
Mahesh SwaminathanDivision of Global HIV & TB, United States Centers for Disease Control and Prevention, Abuja, Nigeria.
Adetifa IfedayoNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Chikwe IhekweazuNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.

Funding

United States Center for Disease Control and Prevention (grant number NU2GGH001976); FCT and Kano), Grant Number: NU2GGH001976
6 · The paper itself

Abstract

SARS-CoV-2 population-based seroprevalence surveys are useful for estimating the extent of SARS-CoV-2 infections, which may be underestimated by COVID-19 case counts. Surveys conducted in October 2020 in four Nigerian states showed that SARS-CoV-2 seroprevalence ranged from 9.3% in Gombe (northeast) to 25.2% in Enugu (southeast) after the first COVID-19 wave, more than 100 and 700 times higher than the official number of COVID-19 cases in these two states, respectively. We conducted a serosurvey after the second COVID-19 wave to evaluate the extent of SARS-CoV-2 infections, attitudes to COVID-19 vaccines, and COVID-19 vaccination coverage in two regions of Nigeria. Using the World Health Organization (WHO) Unity protocol, 34 enumeration areas (EAs) each in the Federal Capital Territory (FCT) (Northcentral Zone) and Kano State (Northwest Zone) were sampled in June 2021, using probability proportional to estimated size; 20 households in one EA were randomly selected. All consenting and assenting members of a household were asked about risk behaviors; adults who were 18 years and above (the eligible population for COVID-19 vaccination in Nigeria) responded to questions on COVID-19 vaccine attitudes and receipt. Blood and nasal/oropharyngeal samples were taken from all consenting and assenting household members. Blood samples collected were tested with the Luminex xMAP® SARS-CoV-2 Multi-Antigen IgG Assay and swabs by reverse-transcriptase-PCR (RT-PCR). Overall response rates were 76.8% in the FCT (n = 1,505 blood draws) and 80.4% in Kano State (n = 2,178 blood draws). Following the second COVID-19 wave in Nigeria, more than 40% of residents in the FCT (40.3%, 95% CI: 34.7-45.9) and Kano State (42.6%, 95% CI: 39.4-45.8) had evidence of prior SARS-CoV-2 infection. There were no active SARS-CoV-2 infections detected by RT-PCR in either the FCT or Kano State. In the FCT and Kano State, 3.4% and 1.6% of people surveyed reported receipt of any COVID-19 vaccine, three months after vaccines were available in country. In the FCT, 77.5% of adults were aware of COVID-19 vaccines, of whom 46.9% reported willingness to receive them. In Kano State, 48.7% of adults were aware of COVID-19 vaccines, of whom 61.1% were willing to receive them. In both regions, about 84% of those reporting unwillingness to accept COVID-19 vaccines cited concerns over vaccine safety. "Serosurvey findings revealed that SARS-CoV-2 infection was far more widespread in both the Federal Capital Territory and Kano State than indicated by reported case numbers. Despite high awareness, COVID-19 vaccine uptake remained low, primarily due to concerns about vaccine safety. These results highlight the urgent need for targeted risk communication to address vaccine hesitancy and improve coverage. Serosurveys provide valuable insights that can guide public health interventions and future pandemic preparedness in Nigeria."

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccination CoverageAdolescentAdultAgedFamily CharacteristicsFemaleHumansMaleMiddle AgedNigeriaSeroepidemiologic StudiesSurveys and QuestionnairesVaccinationCOVID-19 Vaccines

Identifiers

PMID40784905
PMCPMC12336329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.